Prelude Therapeutics Incorporated

NASDAQ:PRLD

Biotechnology

Healthcare
$3.30 -3.22%

-$0.14 today

Market cap
$191.00M
Beta
1.01
P/E (TTM)
-4.5
EPS (TTM)
-$0.94
52W Low $0.75High $5.54

Volume 0.23M

Average 0.38M

PRLD Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Prelude Therapeutics IncorporatedNASDAQ: PRLD

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow grows, but more slowly than its trailing trend

Q1 FY2026 financing cash flow of $314K (cash outflow) rose 96.3% year over year, behind the +9371.4% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at +212.3% a year.

Context

  • Financing cash flow amounted to 204.4% of revenue in FY2025, up 202.7 pp from a year earlier.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +96.3% toward the trailing-twelve-month pace of +9371.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$314K-101.3% QoQ
Last fiscal yearDec 2025
$24.82M+20780.0% YoY
LTMMar 2026
$24.66M+9371.4% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+96.3%——
1 year+20780.0%——
3-year CAGR+212.3%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
24.82M USD
Year-over-year change
+20780.0%
4-year CAGR
-37.7%

Financing Cash Flow vs competitors

How PRLD compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +9371.4% is the highest of 11, against a peer median of +54.6%.
  • Financing cash flow amounts to 147.5% of revenue for PRLD, versus a peer median of 233.6%.
PRLD Competitors
Financing Cash Flow for PRLD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IVAInventiva S.A.FY2025€232M EUR+59.4%+84.0%5175.1%
IMRXImmuneering CorporationLTM Mar 2026$212.95M USD+1074.3%+2184.5%—
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$122.33M USD+380.3%+92.7%—
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$94.16M USD+226.3%-5.1%287.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$57.73M USD+12.7%+11.7%25658.2%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$50.66M USD-51.5%-16.6%179.5%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$42.1M USD+263.6%—60.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$24.66M USD+9371.4%+212.3%147.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$15.99M USD-76.2%—27094.9%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$7.05M USD+49.8%+31.2%62.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$569K USD-68.7%+48.1%4.1%
Peer median (excluding PRLD) —+54.6%+39.6%233.6%

Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.69M)(115.44M)(121.83M)(127.17M)(99.5M)
Depreciation & Amortization915K1.32M1.17M1.77M1.34M
Deferred Income Tax00000
Stock-Based Compensation20.93M25.14M25.62M21.35M11.91M
Change in Working Capital3.63M932K(10.48M)4.22M28.41M
Accounts Receivables00000
Inventory00000
Accounts Payables3.9M(347K)(2.27M)3.31M(3.92M)
Other Working Capital(278K)1.28M(8.21M)911K32.33M
Other Non-Cash Items2.69M4.31M(1.54M)(3.05M)1.53M
Operating Cash Flow(83.53M)(83.73M)(107.06M)(102.89M)(56.3M)
Capital Expenditures(2.32M)(3.02M)(3.51M)(764K)(67K)
Acquisitions (Net)00000
Purchases of Investments(261.48M)(119.22M)(221.63M)(52.69M)(100.87M)
Sales of Investments0203.93M190.5M143.65M154.39M
Other Investing Activities00000
Investing Cash Flow(263.8M)81.69M(34.65M)90.19M53.46M
Debt Repayment000(395K)(208K)
Common Stock Issued161.42M815K135.73M329K25.04M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.47M0664K(54K)(17K)
Financing Cash Flow164.9M815K136.4M(120K)24.82M
Effect of Forex Changes00000
Net Change in Cash(182.44M)(1.22M)(5.31M)(12.82M)21.97M
Free Cash Flow(85.85M)(86.75M)(110.58M)(103.65M)(56.37M)

Prelude Therapeutics Incorporated

NASDAQ:PRLD

Intrinsic Alpha fair value

Locked

Current Price

$3.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.